The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Neo-adjuvant T-VEC plus nivolumab combination therapy for resectable early-stage or metastatic (IIIB-IVM1a) melanoma with injectable disease: The NIVEC trial.
 
Maartje W. Rohaan
No Relationships to Disclose
 
Lisanne P. Zijlker
No Relationships to Disclose
 
Emma H.A. Stahlie
No Relationships to Disclose
 
Viola Franke
No Relationships to Disclose
 
Sofie Wilgenhof
No Relationships to Disclose
 
Vincent van der Noort
No Relationships to Disclose
 
Alexander Christopher Jonathan Van Akkooi
Consulting or Advisory Role - 4SC (Inst); Amgen (Inst); Bristol-Myers Squibb (Inst); Merck/Pfizer (Inst); MSD Oncology (Inst); Novartis (Inst); Pierre Fabre (Inst); Sanofi (Inst); Sirius Medical (Inst)
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Merck/Pfizer (Inst)
Travel, Accommodations, Expenses - Novartis
 
John B. A. G. Haanen
Stock and Other Ownership Interests - Neogene Therapeutics
Consulting or Advisory Role - Achilles Therapeutics (Inst); bioNTech (Inst); Bristol-Myers Squibb (Inst); Immunocore (Inst); Instil Bio (Inst); Iovance Biotherapeutics (Inst); Ipsen (Inst); Molecular Partners (Inst); MSD Oncology (Inst); Neogene Therapeutics; Novartis (Inst); Pfizer (Inst); POEM Health (Inst); Roche/Genentech (Inst); Sanofi (Inst); T-Knife (Inst); Third Rock Ventures (Inst)
Research Funding - Amgen (Inst); Asher Biotherapeutics (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Neon Therapeutics (Inst); Novartis (Inst)